Novartis wins big OTC deal.
|
DEALS |
|||
|
WHO |
WITH |
WHAT |
SCOOP |
|
Novartis |
Bristol-Myers Squibb |
$660 million acquisition of US and Canadian OTC division |
Novartis gains rights to a broad range of OTC drugs, including Excedrin and Comtrex. |
|
Omnicare |
excelleRx |
$269 million buyout |
Omnicare gains a provider of comprehensive pharmaceutical care services, primarily for hospice patients. |
|
McKesson |
D&K Healthcare Resources |
$207 million buyout |
McKesson adds a regional drug distributor to its operations. |
|
Sosei |
Arakis |
$187.4 million buyout |
The deal expands Sosei's pipeline with several compounds in development, including a $375 million global partnership with Novartis for its lead product AD 237. |
|
Aptuit |
Quintiles Transnational |
$125 million business unit acquisition |
The units will be reorganized by Aptuit into three global business lines: Preclinical Technologies, Pharmaceutical Sciences and Packaging & Logistics. |
|
Roche Group |
GlycArt Biotechnology |
Buyout |
Roche gains new technology technology for enhancing the efficacy of antibodies. |
|
American Pacific |
Aerojet Fine Chemicals |
Buyout for $119 million plus liabilities |
American Pacific buys an established player in the sale of active pharmaceutical ingredients. |
|
Assay Designs |
Stressgen Bioreagents |
Acquisition |
Stressgen develops and markets antibodies, proteins and related kits to life sciences researchers worldwide. |
|
Hi-Tech Pharmacal |
Rodlen Laboratories |
$4.4 million brand buyout |
Hi-Tech gains control of Zostrix OTC analgesic creams. |